Serina Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016
Net Income	-14.8	-10.46	-8.68	-10.87	-12.15	-7.5	-6.58	-15.49
Depreciation & Amortization	0.13	0.13	0.13	1.26	0.95	0.54	0.68	0.85
Share-Based Compensation	0.65	0.76	1	0.91	1.91	1.29	0.34	0.98
Other Operating Activities	6.22	3.63	-0.31	0.88	-0.86	-2.32	-0.73	5.24
Operating Cash Flow	-7.8	-5.94	-7.86	-7.82	-10.16	-8	-6.29	-8.43
Capital Expenditures	0	0	0	-0.02	-0.64	-0.02	-0	-0.02
Acquisitions	0	0	0.42	0	0	0	-0	0
Change in Investments	-10	0	0.25	0	0.35	3.22	0	0
Other Investing Activities	-	-	-	-	-0.07	-1.87	0.01	-0.01
Investing Cash Flow	-10	0	0.67	-0.02	-0.36	1.33	0.01	-0.03
Share Issuance / Repurchase	0	0	0.5	0	4.5	6	10	0
Debt Issued / Paid	17.5	6	6.75	6.12	1.77	0	0	0
Other Financing Activities	-	-	-	-0.16	-	-	3.28	7.25
Financing Cash Flow	17.5	6	7.25	5.96	6.27	6	13.28	7.25
Exchange Rate Effect	0	0	0	0	0	0	0.12	-0.04
Net Cash Flow	-0.3	0.06	0.06	-1.88	-4.26	-0.67	7.12	-1.24
Free Cash Flow	-7.8	-5.94	-7.86	-7.84	-10.8	-8.02	-6.29	-8.45
Free Cash Flow Margin	-5492.96%	-17467.65%	-5454.86%	-2170.91%	-625.06%	-574.21%	-447.72%	-507.20%
Free Cash Flow Per Share	-7.23	-5.50	-7.29	-7.32	-10.19	-8.07	-7.21	-10.32

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).